rkin B.C., Nahin R.L. et al. Ginkgo biloba and risk of cancer: secondary analysis of the Ginkgo Evaluation of Memory (GEM) Study. Pharmacoepidemiol Drug Saf. 2010 Jul;19(7):694-8. doi: 10.1002/pds.1979. www.ncbi.nlm.nih.gov/ pubmed/20582906 (дата обращения: 15.01.2021).
180. National Toxicology Program. Toxicology and carcinogenesis studies of Ginkgo biloba extract (CAS No. 90045-36-6) in F344/N rats and B6C3F1/N mice (Gavage studies). Natl Toxicol Program Tech Rep Ser. 2013 Mar;(578):1-183. www.ncbi.nlm. nih.gov/pubmed/23652021 (дата обращения: 16.01.2021).
181. Antoniades C., Antonopoulos A.S., Tousoulis D. et al. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J. 2009 Jan;30(1):6-15. doi: 10.1093/eurheartj/ehn515. www.ncbi.nlm.nih.gov/ pubmed/19029125 (дата обращения: 16.01.2021).
182. Cole B.F., Baron J.A., Sandler R.S. et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007 Jun 6;297(21):2351-9. doi: 10.1001/ jama.297.21.2351. www.ncbi.nlm.nih.gov/pubmed/17551129 (дата обращения: 16.01.2021).
183. Rodriguez J.M., Miranda D., Bunout D. et al. Folates Induce Colorectal Carcinoma HT29 Cell Line Proliferation Through Notch1 Signaling. Nutr Cancer. 2015;67(4):706-
11. doi: 10.1080/01635581.2015.1011285. www.ncbi.nlm.nih.gov/pubmed/25802929 (дата обращения: 16.01.2021).
184. Chen F., Du M., Blumberg J.B. et al. Association Among Dietary Supplement Use, Nutrient Intake, and Mortality Among U.S. Adults: A Cohort Study. Ann Intern Med. 2019 May 7;170(9):604–613. doi: 10.7326/M18-2478. www.ncbi.nlm.nih.gov/ pubmed/30959527 (дата обращения: 16.01.2021).
185. Tahmasebi K., Amani R., Nazari Z. et al. Association of Mood Disorders with Serum Zinc Concentrations in Adolescent Female Students. Biol Trace Elem Res. 2017 Aug;178(2):180–188. doi: 10.1007/s12011-016-0917-7. www.ncbi.nlm.nih.gov/ pubmed/28064416 (дата обращения: 16.01.2021).
186. Lai J., Moxey A., Nowak G. et al. The efficacy of zinc supplementation in depression: systematic review of randomised controlled trials. J Affect Disord. 2012 Jan;136(1–2):e31-e39. doi: 10.1016/j.jad.2011.06.022. www.ncbi.nlm.nih.gov/ pubmed/21798601 (дата обращения: 16.01.2021).
187. Lamore S.D., Cabello C.M., Wondrak G.T. The topical antimicrobial zinc pyrithione is a heat shock response inducer that causes DNA damage and PARP-dependent energy crisis in human skin cells. Cell Stress Chaperones. 2010 May;15(3):309-22. doi: 10.1007/s12192-009-0145-6. www.ncbi.nlm.nih.gov/pubmed/19809895 (дата обращения: 16.01.2021).
188. Shi Z., Chu A., Zhen S. et al. Association between dietary zinc intake and mortality among Chinese adults: findings from 10-year follow-up in the Jiangsu Nutrition Study. Eur J Nutr. 2018 Dec;57(8):2839–2846. doi: 10.1007/s00394-017-1551-7. www.ncbi. nlm.nih.gov/pubmed/29022177 (дата обращения: 16.01.2021).
189. Rothwell P.M., Price J.F., Fowkes F.G. et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012 Apr 28;379(9826):1602-
12. doi: 10.1016/S0140-6736(11)61720-0. www.ncbi.nlm.nih.gov/pubmed/22440946 (дата обращения: 16.01.2021).
190. Rothwell P.M., Wilson M., Elwin C.E. et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010 Nov 20;376(9754):1741-50. doi: 10.1016/S0140-6736(10)61543-7. www.ncbi.nlm.nih.gov/pubmed/20970847 (дата обращения: 16.01.2021).
191. McNeil J.J., Nelson M.R., Woods R.L. et al. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med. 2018 Oct 18;379(16):1519–1528. doi: 10.1056/NEJMoa1803955. www.ncbi.nlm.nih.gov/pubmed/30221595 (дата обращения: 16.01.2021).
192. Weimer S., Priebs J., Kuhlow D. et al. D-Glucosamine supplementation extends life span of nematodes and of ageing mice. Nat Commun. 2014 Apr 8;5:3563. doi: 10.1038/ncomms4563. www.ncbi.nlm.nih.gov/pubmed/24714520 (дата обращения: 16.01.2021).
193. Bell G.A., Kantor E.D., Lampe J.W. et al. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012 Aug;27(8):593–603. doi: 10.1007/s10654-012-9714-6. www.ncbi.nlm.nih.gov/pubmed/22828954 (дата обращения: 16.01.2021).
194. Navarro S.L., White E., Kantor E.D. et al. Randomized trial of glucosamine and chondroitin supplementation on inflammation and oxidative stress biomarkers and plasma proteomics profiles in healthy humans. PLoS One. 2015 Feb 26;10(2):e0117534. doi: 10.1371/journal.pone.0117534. www.ncbi.nlm.nih.gov/pubmed/25719429 (дата обращения: 16.01.2021).
195. Esfandiari H., Pakravan M., Zakeri Z. et al. Effect of glucosamine on intraocular pressure: a randomized clinical trial. Eye (Lond). 2017 Mar;31(3):389–394. doi: 10.1038/ eye.2016.221. www.ncbi.nlm.nih.gov/m/pubmed/27768119 (дата обращения: 16.01.2021).
196. Choudhari A.S., Mandave P.C., Deshpande M. et al. Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice. Front Pharmacol. 2020 Jan 28;10:1614. doi: 10.3389/fphar.2019.01614. www.ncbi.nlm.nih.gov/pubmed/32116665 (дата обращения: 16.01.2021).
197. Mei Z., Liang M., Li L. et al. Effects of statins on cancer mortality and progression: A systematic review and meta-analysis of 95 cohorts including 1,111,407 individuals. Int J Cancer. 2017 Mar 1;140(5):1068–1081. doi: 10.1002/ijc.30526. www.ncbi.nlm.nih. gov/pubmed/27859151 (дата обращения: 16.01.2021).
198. Chen Y., Li X., Zhang R. et al. Effects of statin exposure and lung cancer survival: A meta-analysis of observational studies. Pharmacol Res. 2019 Mar;141:357–365. doi: 10.1016/j.phrs.2019.01.016. www.ncbi.nlm.nih.gov/pubmed/30641276 (дата обращения: 16.01.2021).
199. Funao K., Matsuyama M., Kawahito Y. et al. Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol Rep. 2008 Aug;20(2):295–300. www.ncbi.nlm.nih.gov/pubmed/18636189 (дата обращения: 16.01.2021).
200. Feng X., Luo Z., Ma L. et al. Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-5/AMPK pathway. J Cell Mol Med. 2011 Jul;15(7):1572-81. doi: 10.1111/j.1582–4934.2010.01085.x. www. ncbi.nlm.nih.gov/pubmed/20477906 (дата обращения: 16.01.2021).
201. Недогода С.В. Сартаны второго поколения: расширение терапевтических возможностей. Рациональная Фармакотерапия в Кардиологии. 2011;7(4):477–482. www.rpcardio.com/jour/article/viewFile/865/898 (дата обращения: 16.01.2021).
202. Frampton J.E. Telmisartan: a review of its use in cardiovascular disease prevention. Drugs. 2011 Apr 16;71(6):651-77. doi: 10.2165/11206710-00000000000000. www.ncbi.nlm.nih.gov/pubmed/21504246 (дата обращения: 16.01.2021).
203. Volpe M. Should all patients at high cardiovascular risk receive renin-angiotensin system blockers? QJM. 2012 Jan;105(1):11–27. doi: 10.1093/qjmed/hcr190. www.ncbi. nlm.nih.gov/pubmed/22011630 (дата обращения: 16.01.2021).
204. Ozeki K., Tanida S., Morimoto C. et al. Telmisartan inhibits cell proliferation by blocking nuclear translocation of ProHB-EGF C-terminal fragment in colon cancer cells. PLoS One. 2013;8(2):e56770. doi: 10.1371/journal.pone.0056770. www.ncbi.nlm. nih.gov/pubmed/23451083 (дата обращения: 16.01.2021).
205. Tamaki Y., Nakade Y., Yamauchi T. et al. Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis. J Gastroenterol. 2013 Apr;48(4):491–503. doi: 10.1007/s00535-012-0651-7. www.ncbi.nlm.nih.gov/ pubmed/22886508 (дата обращения: 16.01.2021).
206. Zhao Y.T., Li P.Y., Zhang J.Q. et al. Angiotensin II Receptor Blockers and Cancer Risk: A Meta-Analysis of Randomized Controlled Trials. Medicine (Baltimore). 2016 May;95(18):e3600. doi: 10.1097/MD.0000000000003600. www.ncbi.nlm.nih.gov/ pubmed/27149494 (дата обращения: 16.01.2021).
207. Datzmann T., Fuchs S., Andree D. et al. Systematic review and metaanalysis of randomised controlled clinical trial evidence refutes relationship between pharmacotherapy with angiotensin-receptor blockers and an increased risk of cancer. Eur J Intern Med. 2019 Jun;64:1–9. doi: 10.1016/j.ejim.2019.04.019. www.ncbi.nlm.nih. gov/pubmed/31060961.
208. Tascilar K., Azoulay L., Dell’Aniello S. et al. The Use of Telmisartan and the Incidence of Cancer. Am J Hypertens. 2016 Dec 1;29(12):1358–1365. doi: 10.1093/ajh/ hpw095. www.ncbi.nlm.nih.gov/pubmed/27557862 (дата обращения: 16.01.2021).
209. Barron T.I., Connolly R.M., Sharp L. et al. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol. 2011 Jul 1;29(19):2635-44. doi: 10.1200/JCO.2010.33.5422. www.ncbi.nlm.nih.gov/pubmed/21632503 (дата обращения: 16.01.2021).
210. Powe D.G., Voss M.J., Zanker K.S. et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010 Nov;1(7):628-38. doi: 10.18632/oncotarget.101009. www.ncbi.nlm. nih.gov/pubmed/21317458 (дата обращения: 16.01.2021).
211. Choy C., Raytis J.L., Smith D.D. et al. Inhibition of 02-adrenergic receptor reduces triple-negative breast cancer brain metastases: The potential benefit of perioperative 0-blockade. Oncol Rep. 2016 Jun;35(6):3135-42. doi: 10.3892/or.2016.4710. www. ncbi.nlm.nih.gov/pubmed/27035124 (дата обращения: 16.01.2021).
212. Montoya A., Amaya C.N., Belmont A. et al. Use of non-selective 0-blockers is associated with decreased tumor proliferative indices in early stage breast cancer. Oncotarget. 2017 Jan 24;8(4):6446–6460. doi: 10.18632/oncotarget.14119. www.ncbi. nlm.nih.gov/pubmed/28031536 (дата обращения: 16.01.2021).
213. Watkins J.L., Thaker P.H., Nick A.M. et al. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer. 2015 Oct 1;121(19):3444-51. doi: 10.1002/cncr.29392. www.ncbi.nlm.nih.gov/pubmed/26301456 (дата обращения: 16.01.2021).